Ian Karp
Head of Investor Relations
Replay available
Collegium Pharmaceutical, Inc. (NASDAQ: COLL) Q1 2025 earnings conference call, held 2025-05-08. Replay captured from the company's public earnings webcast.

Head of Investor Relations
President and Chief Executive Officer
Chief Commercial Officer
Chief Financial Officer
Analyst, Truist Securities
Analyst, Needham & Co.
Analyst, Piper Sandler
Watch the replay and follow the connected company analysis, news, and investor updates for Collegium Pharmaceutical, Inc..
WEBVTT 00:00:00.031 -- 00:00:05.476 Greetings and welcome to the Collegium Pharmaceutical First Quarter 2025 Earnings 00:00:05.476 -- 00:00:10.161 Conference Call. At this time, all participants are in a listen-only mode. 00:00:10.161 -- 00:00:13.184 A question and answer session will follow the formal presentation. 00:00:13.184 -- 00:00:17.929 If anyone should require operator assistance during this conference call, please press 00:00:17.929 -- 00:00:23.675 star zero on your telephone keypad. Please note that this conference call is being recorded. 00:00:23.675 -- 00:00:28.660 I will now turn the call over to Ian Karp, Head of Investor Relations at Collegium. 00:00:28.660 -- 00:00:31.641 Thank you. You may begin. 00:00:31.722 -- 00:00:35.867 Thanks, Maria, and welcome to Collegium Pharmaceuticals' first quarter earnings conference 00:00:35.867 -- 00:00:40.754 call. I'm joined today by Vikram Karnani, our President and Chief Executive Officer, 00:00:40.754 -- 00:00:45.801 Colleen Tupper, our Chief Financial Officer, and Scott Dreyer, our Chief Commercial Officer. 00:00:45.801 -- 00:00:49.565 Before we begin today's call, we want to remind participants that none of the information 00:00:49.565 -- 00:00:53.511 presented today is intended to be promotional and that any forward-looking statements 00:00:53.511 -- 00:00:57.796 made today are made pursuant to the safe harbor provisions of the Private Securities 00:00:57.796 -- 00:01:00.562 Litigation Reform Act of 1995. 00:01:00.562 -- 00:01:04.727 Your caution that such forward-looking statements involve risks and uncertainties, including 00:01:04.727 -- 00:01:08.271 and without limitation, the risk that we may not be able to successfully commercialize 00:01:08.271 -- 00:01:13.357 our products, that we may incur significan...